Aldesleukin Recruiting Phase 2 Trials for Systemic Lupus Erythematosus (SLE) Basic Science

IndicationsStatusPurposePhase
RecruitingBasic Science2
clinicaltrials.gov IdentifierTitleDrugs
NCT03312335Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus